GENE ONLINE|News &
Opinion
Blog

.

Зеркало официального сайта всегда доступно для входа на Мостбет, даже при ограничениях. Скачать Mostbet – это шаг к удобству и азартным развлечениям.

Если вы ищете место для увлекательных ставок, обратите внимание на Joycasino, где лучшие предложения для игроков ждут вас.
last added cars
2022-05-27| Trials & Approvals

Janssen’s First Cell Therapy Gets Europe’s Approval for Multiple Myeloma

by Fujie Tham
Share To

Janssen’s first cell therapy – Carvykti, was granted conditional marketing authorization for treatment of adults with relapsed and refractory multiple myeloma (RRMM) by the European Commission (EC). The therapeutic developed jointly with China-based Legend Biotech was approved by the FDA earlier in February in the US.

Multiple myeloma is a rare cancer of blood plasma cells, a type of white blood cell that manufactures antibodies and is found in the bone marrow. In multiple myeloma, proliferation of plasma cells is unregulated, causing abnormal, immature plasma cells to multiply and fill up the bone marrow spaces. When plasma cells turn cancerous, they no longer protect the body and produce abnormal proteins that can cause issues affecting the kidneys, bones, or blood.

Related article: J&J, Legend’s Cell Therapy Gets FDA Nod 

Addressing Unmet Needs for New Multiple Myeloma Treatments

 

Carvykti’s active ingredient is ciltacabtagene autoleucel, a genetically modified autologous T cell immunotherapy consisting of modified T-cells bearing a chimeric antigen receptor (CAR) that targets B cell maturation antigen (BCMA). BCMA is expressed primarily on the surface of malignant multiple myeloma B-lineage cells, late-stage B cells, and plasma cells. Upon binding to BCMA-expressing cells, the CAR promotes T cell activation, expansion, and the elimination of cancerous cells.

As there is no cure for multiple myeloma, there is an urgent demand for Carvykti. Patients who already received immunomodulatory agents, proteasome inhibitors, and monoclonal antibodies, have recurring disease, or stopped responding to previous treatments can now be treated with a different approach. 

The pharma giant projected peak annual sales of Carvykti to exceed $5 billion. Based on a deal inked in 2017, Johnson & Johnson and Legend will divide the profits 30-70 in China and 50-50 in all other countries. Carvykti is currently under review in Japan, while Legend Biotech secured a breakthrough therapy designation in China, the first product to be granted such a label.

©www.geneonline.com All rights reserved. Collaborate with us: [email protected]
Related Post
Major Win – FDA Grants Fast Track Designation to Adicet Bio’s ADI-001 for Lupus Disease
2025-02-07
Silicon Valley in the Crosshairs as EU Readies to Strike U.S. Big Tech
2025-02-06
Six Game-Changing Cancer Treatments Built for Unstoppable Growth in 2025 – Part I
2024-12-11
LATEST
Beyond Pouch Packaging: Hanmi Pharmaceutical Introduces a New Automated Vial Dispensing Solution in Canada and the United States
2025-02-13
NASA Says There’s a 1 in 43 Chance an Asteroid 2024 YR4 Could Hit Earth in 2032—Should We Worry?
2025-02-13
Sodium Channel Targeting: What the Latest FDA Non-Opioid Approval Reveals About the Next Big Thing in Pain Relief
2025-02-12
Novartis Reclaims Abelacimab in $925M Deal to Boost Cardiovascular Portfolio
2025-02-12
GLP-1 Weight Loss Drugs Might Cause Blindness
2025-02-11
South Korea’s Olix Strikes $660M Deal with Eli Lilly for Phase 1 MASH candidate
2025-02-11
22 USA States Sue Trump Administration for Slashing Critical Medical Research Funding
2025-02-11
EVENT
2025-02-19
Healthcare Conference Taipei 2025
Taipei, Taiwan
2025-03-04
MIXiii Health-Tech.IL
Jerusalem, Israel
2025-03-05
Medical Japan
Osaka, Japan
2025-03-17
BIO-Europe Spring 2025
Milan, Italy
2025-04-21
World Vaccine Congress Washington 2025
Washington, U.S.A
Scroll to Top